Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05626465
Starting soon Observational

Biomarker-s of Abusive Head Trauma by Proteomics

NCT05626465 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Geneva
Phase
Observational
Started
2023-02
Last updated
2023-01-13

Condition(s) studied

Abuse, ChildProtein Disorder, Blood

Investigational drug(s) / intervention(s)

Blood test

Blood test: Proteomic analyses on serum

Study summary

The aim of our study is to highlight biomarker-s of Abusive Head Trauma by proteomics analyses on the serum of child victims of abuse.

Eligibility

Sex
ALL
Min age
—
Max age
2 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age : 0-2 y.o * Medical consultation for malaise, seizure (without fever), loss of consciousness, traumatic bain injury, or cranioplasty * Blood test during medical care * Accepted informed consent Exclusion Criteria: * Refused informed consent * For control groups : medical history of child abuse * For AHT group : rare metabolic disease (Menkes, etc..)

Primary outcome measure(s)

  • Highlight novel biomarker-s of AHT — Hospital admission to discharge (up to 3 days)
    Proteomic analyses will be made on serum of infant victim of AHT. Results will be compare with control groups (traumatic brain injury, cranioplasty, malaise).

Trial sites (2)

FacilityCityRegionStatus
Ginhoux Thiphanie Lyon Rhône
Wiskott Kim Geneva Switzerland

More University Hospital, Geneva trials in France

Atrial Fibrillation Ablation Versus Atrioventricular Nodal Ablation with Conduction System Pacing in Heart Failure Recruiting
@neurIST : Intregrated Biomedical Informatics for the Management of Cerebral Aneurysms Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05626465 on ClinicalTrials.gov ↗ ← All trials in France